Skip to main content
Top

22-06-2023 | Diffuse Large B-Cell Lymphoma | Congress News | News

EHA 2023

Prognosis patients with R/R DLBCL in pre-CAR T era poor

MedNet.nl: A Dutch population study shows that survival of patients with early relapsing/refractory (R/R) diffuse large cell B cell lymphoma (DLBCL) treated with second-line intensive therapy with or without autologous stem cell transplantation is poor.

Related topics

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine